Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Takhzyro (lanadelumab-flyo) is a fully human monoclonal antibody that functions as a plasma kallikrein inhibitor. It is indicated for the prophylaxis of hereditary angioedema (HAE) attacks in patients aged 2 years and older. By selectively inhibiting plasma kallikrein, Takhzyro helps to reduce excessive bradykinin production, a key mediator in the pathophysiology of HAE, thereby preventing the characteristic swelling episodes associated with the condition. Takhzyro is not intended for acute treatment of HAE attacks.
| Fact Table | |
| Formula | C6420H9946N1714O2010S46 |
| License | US FDA, EMA |
| Bioavailability | ~55% (subcutaneous) |
| Legal status | Prescription only (Rx-only) |
| Chemical Name | Lanadelumab |
| Elimination half-life | 14.8 days |
| Dosage (Strength) | 300 mg/2 mL solution for subcutaneous injection; once every 2 to 4 weeks |
| Pregnancy | Consult a doctor (Category not assigned) |
| Brands | Takhzyro |
| Protein binding | Not applicable (monoclonal antibody) |
| PubChem CID | 121374248 |
| MedlinePlus | a619038 |
| ChEBI | Not available |
| ATC code | B06AC05 |
| DrugBank | DB14782 |
| KEGG | D11222 |
| Routes of administration | Subcutaneous |
Takhzyro is administered via subcutaneous injection. The recommended starting dose for patients aged 12 years and older is 300 mg every two weeks. For patients who are well-controlled (e.g., attack-free) on this regimen, a dose of 300 mg every four weeks may be considered. In pediatric patients aged 2 to <12 years, the dosage is weight-based:
26 to <40 kg: 150 mg every two weeks
=40 kg: 300 mg every two weeks
Takhzyro should be administered by a healthcare professional or self-injected after appropriate training. It should be injected into the abdomen, thigh, or upper arm, rotating sites with each administration.
Each single-dose prefilled syringe or vial contains 300 mg of lanadelumab-flyo in 2 mL solution (150 mg/mL). Inactive ingredients include L-histidine, L-histidine hydrochloride monohydrate, sodium chloride, polysorbate 80, and water for injection.
Takhzyro is contraindicated in patients with known hypersensitivity to lanadelumab or any of its components. Hypersensitivity reactions, including anaphylaxis, have been reported and require immediate discontinuation of therapy.
Use Takhzyro with caution in patients with a history of hypersensitivity. Although not studied in pregnant or lactating women, the potential benefits and risks should be considered when prescribing to this population. Immunogenicity has been observed in some patients, which may affect drug efficacy or increase the risk of hypersensitivity. Takhzyro should not be used to treat acute HAE attacks; patients should have access to on-demand rescue medication at all times. Clinical monitoring is recommended during initiation and periodically during treatment.
Common and serious side effects reported with Takhzyro include:
Injection site reactions (pain, redness, bruising)
Upper respiratory tract infections
Headache
Dizziness
Rash
Diarrhea
Muscle pain
Elevated liver enzymes (in rare cases)
Hypersensitivity reactions, including anaphylaxis (rare)
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews